<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LEVOBUPIVACAINE</span><br/>(lev-o-bu-piv'a-cane)<br/><span class="topboxtradename">Chirocaine<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">local anesthetic (ester type)</span><br/><b>Prototype: </b>Procaine HCl<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg/mL, 5 mg/mL, 7.5 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Decreases sodium flux into nerve cell, inhibiting initial depolarization, and prevents propagation and conduction of nerve
         impulse.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Progression of anesthesia is manifested clinically as sequential loss of nerve function: pain, temperature, touch, proprioception
         and skeletal muscle tone.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Local or regional anesthesia for surgery and obstetrics, and for postoperative pain management.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to levobupivacaine or any other local anesthetic of the amide type (e.g., procaine, bupivacaine); acidosis;
         cardiac heart block; severe hemorrhaging; cerebral spinal disease; septicemia. Safe use during pregnancy (category B) other
         than labor and delivery, or in children is not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Surgical Anesthesia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Epidural</span> 2550 mg <span class="rdroute">Nerve Block</span> 12 mg/kg <span class="rdroute">Infiltration</span> 150 mg<br/><br/><span class="indicationtitle">Pain Management</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Epidural</span> 525 mg/h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Epidural</span><br/><ul>
<li>Aspirate for blood and cerebrospinal fluid prior to original dose and all subsequent doses to avoid injection into intravascular
            and intrathecal spaces.
         </li>
<li>Use lowest effective dose to achieve desired outcome.</li>
<li>Use either the 0.125% or 0.25% solution for postoperative pain management; give 525 mg/h (410 mL/h).</li>
</ul>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<small>ALKALINE SOLUTIONS</small> (e.g., <b>aminophylline, phenobarbital, sodium bicarbonate</b>). <span class="incompattype"> Y-site:</span>
<small>ALKALINE SOLUTIONS</small> (e.g., <b>aminophylline,</b>
<b>phenobarbital,</b>
<b>sodium bicarbonate</b>). 
      </p>
<ul>
<li>Store at 20°25° C (86°77° F); brief excursions beyond this range are tolerated.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever, pain, back pain, paresthesia. <span class="typehead">CV:</span>
<span class="speceff-common">Hypotension,</span> abnormal ECG, bradycardia, tachycardia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting,</span> constipation, enlarged abdomen, dyspepsia. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Anemia</span>. <span class="typehead">Metabolic:</span> Hypothermia. <span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead">Skin:</span> Pruritus. <span class="typehead">Urogenital:</span> Albuminuria, hematuria, fetal distress, delivery delayed. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification">calcium channel blockers</span>, <b>clarithromycin,</b>
<b>erythromycin,</b>
<b>ketoconazole,</b>
<b>ritonavir</b> may potentiate effect. <b>Omeprazole,</b>
<b>phenobarbital,</b>
<b>phenytoin,</b>
<b>rifampin</b> may decrease effect. Additive adverse effects and toxicity with other <span class="classification">local anesthetics</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 30 min. <span class="typehead">Distribution:</span> &gt;97% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A4 and CYP1A2. <span class="typehead">Elimination:</span> 71% excreted in urine, 24% excreted in feces. <span class="typehead">Half-Life:</span> 3.3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and immediately report: Hypotension, bradycardia, heart block (seen with inadvertent intravascular injection).</li>
<li>Monitor continuously cardiovascular status, respiratory function, level of consciousness, and sensory/motor function.</li>
<li>Supervise ambulation as dizziness is a common side effect.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to physician: Tremors, lightheadedness, numbness and tingling around the mouth.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>